NASDAQ:BCEL

Atreca Stock Forecast, Price & News

$11.98
+0.02 (+0.17 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.50
Now: $11.98
$12.19
50-Day Range
$11.41
MA: $14.74
$18.46
52-Week Range
$11.01
Now: $11.98
$25.03
Volume120,575 shs
Average Volume254,383 shs
Market Capitalization$441.24 million
P/E RatioN/A
Dividend YieldN/A
Beta0.08
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology. Atreca, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BCEL
CUSIPN/A
CIKN/A
Phone650-595-2595
Employees130
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.68 per share

Profitability

Net Income$-67,480,000.00

Miscellaneous

Market Cap$441.24 million
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable

Headlines

Atreca Target of Unusually High Options Trading (NASDAQ:BCEL)
April 21, 2021 |  americanbankingnews.com
Form 10-K Atreca, Inc. For: Dec 31 - StreetInsider.com
February 27, 2021 |  streetinsider.com
What's in Store for Mallinckrodt (MNKKQ)This Earnings Season?
February 13, 2021 |  markets.businessinsider.com
See More Headlines

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

273rd out of 2,024 stocks

Pharmaceutical Preparations Industry

119th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$11.98
+0.02 (+0.17 %)
(As of 04/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BCEL News and Ratings via Email

Sign-up to receive the latest news and ratings for BCEL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Atreca (NASDAQ:BCEL) Frequently Asked Questions

Is Atreca a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atreca in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Atreca stock.
View analyst ratings for Atreca
or view top-rated stocks.

What stocks does MarketBeat like better than Atreca?

Wall Street analysts have given Atreca a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Atreca wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Atreca's next earnings date?

Atreca is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Atreca
.

How were Atreca's earnings last quarter?

Atreca, Inc. (NASDAQ:BCEL) released its earnings results on Thursday, February, 25th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.02.
View Atreca's earnings history
.

How has Atreca's stock price been impacted by Coronavirus?

Atreca's stock was trading at $17.62 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BCEL stock has decreased by 32.0% and is now trading at $11.98.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for BCEL?

4 brokerages have issued 12 month price objectives for Atreca's shares. Their forecasts range from $25.00 to $33.00. On average, they anticipate Atreca's share price to reach $29.33 in the next twelve months. This suggests a possible upside of 144.9% from the stock's current price.
View analysts' price targets for Atreca
or view top-rated stocks among Wall Street analysts.

Who are Atreca's key executives?

Atreca's management team includes the following people:
  • Mr. John A. Orwin, Pres, CEO & Director (Age 56, Pay $725.01k)
  • Dr. Tito A. Serafini, Founder, Chief Strategy Officer & Director (Age 58, Pay $637.49k)
  • Dr. Norman Michael Greenberg Ph.D., Chief Scientific Officer (Age 61, Pay $683.43k)
  • Mr. Herbert C. Cross, Chief Financial Officer (Age 49)
  • Dr. Yann Chong Tan, Chief Technologist
  • Ms. Courtney J. Phillips J.D., Gen. Counsel & Corp. Sec. (Age 46)
  • Dr. Daniel Emerling, Sr. VP of Research
  • Dr. Jonathan Benjamin M.D., Ph.D., Sr. VP of Clinical Research

What is John Orwin's approval rating as Atreca's CEO?

2 employees have rated Atreca CEO John Orwin on Glassdoor.com. John Orwin has an approval rating of 100% among Atreca's employees. This puts John Orwin in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Atreca's key competitors?

What other stocks do shareholders of Atreca own?

When did Atreca IPO?

(BCEL) raised $126 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers.

What is Atreca's stock symbol?

Atreca trades on the NASDAQ under the ticker symbol "BCEL."

Who are Atreca's major shareholders?

Atreca's stock is owned by many different institutional and retail investors. Top institutional shareholders include Mcdonald Partners LLC (0.06%). Company insiders that own Atreca stock include Guy Cavet, John A Orwin, Norman Michael Greenberg, Tito Serafini and William Hewitt Robinson.
View institutional ownership trends for Atreca
.

Which major investors are selling Atreca stock?

BCEL stock was sold by a variety of institutional investors in the last quarter, including Mcdonald Partners LLC. Company insiders that have sold Atreca company stock in the last year include Norman Michael Greenberg, Tito Serafini, and William Hewitt Robinson.
View insider buying and selling activity for Atreca
or view top insider-selling stocks.

How do I buy shares of Atreca?

Shares of BCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atreca's stock price today?

One share of BCEL stock can currently be purchased for approximately $11.98.

How much money does Atreca make?

Atreca has a market capitalization of $441.24 million. The company earns $-67,480,000.00 in net income (profit) each year or ($4.26) on an earnings per share basis.

How many employees does Atreca have?

Atreca employs 130 workers across the globe.

What is Atreca's official website?

The official website for Atreca is www.atreca.com.

Where are Atreca's headquarters?

Atreca is headquartered at 500 SAGINAW DRIVE FIRST FLOOR, REDWOOD CITY CA, 94063.

How can I contact Atreca?

Atreca's mailing address is 500 SAGINAW DRIVE FIRST FLOOR, REDWOOD CITY CA, 94063. The company can be reached via phone at 650-595-2595 or via email at [email protected]


This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.